Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics

Summary

Sodium pyruvate in sodium chloride solution will be delivered by nebulization to the lungs. It is believed that this administration will produce bronchodilation in asthmatics as determined by improvement in FEV1. FEV1 is a measure of lung function, and will be determined after administration of sodium pyruvate. The study is a blinded, so subjects may receive either the sodium pyruvate or a sodium chloride placebo. The primary endpoint will be the improvement of FEV1 after 15 minutes in subjects receiving sodium pyruvate compared to the FEV1 of subjects receiving the sodium chloride placebo.

Timeline

Start

2006-01

Primary completion

2006-09

Completion

2006-09

Outcome

Outcome not reported

Stopped: “Patients did not respond to therapy”

Drugs

Indications

No indication recorded.